TENX - Tenax Therapeutics reports retirement of CEO and $10M PIPE financing

Tenax Therapeutics (TENX) announces that effective July 13, 2021, Mr. Anthony A. DiTonno will retire as Chief Executive Officer ((CEO)) and Director of the Company, following a successful decade of service with the Company.The Board has appointed Mr. Christopher T. Giordano to serve as CEO and a Director of the Company, effective July 14.Mr. Giordano, most recently served as President of IQVIA Biotech and IQVIA MedTech.In addition, the company has entered into agreement with a single institutional investor for the issuance and sale of 4,773,269 units at $2.095/unit.Each unit consists of one unregistered pre-funded warrant to purchase one common share and one unregistered warrant to purchase one share of common stock.In aggregate, 9,546,538 shares of the Company’s common stock are underlying the warrants. The unregistered pre-funded warrants have an exercise price of $0.0001/share. The five and one-half years unregistered warrants have an exercise price of $1.97/share. The aggregate gross proceeds

For further details see:

Tenax Therapeutics reports retirement of CEO and $10M PIPE financing